Cadian Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cadian Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-74,200	Closed	-$7.77M	–	64
2015 Q4	$7.77M	Sell	74,200 -65,000	-47%	-$6.79M	0.28%	63
2015 Q3	$14.7M	Sell	139,200 -180,800	-57%	-$24.2M	0.53%	50
2015 Q2	$43.8M	Sell	320,000 -5,000	-2%	-$620K	1.29%	22
2015 Q1	$40.5M	Buy	325,000 +110,000	+51%	+$11.7M	1.09%	19
2014 Q4	$19.4M	Buy	+215,000	New	+$17.9M	0.49%	37

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cadian Capital Management's BMRN Position: Q1 2016 in Review

Cadian Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2016, closing a stake of 74,200 shares — an estimated $7.77M sold.

Cadian Capital Management first reported a position in BMRN in Q4 2014 and held it in 5 quarters. The position peaked at $43.8M in Q2 2015. 391 funds tracked by Wall St. Rank hold BMRN as of Q1 2016.

Cadian Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Cadian Capital Management sold 74,200 BioMarin Pharmaceuticals shares in Q1 2016, an estimated $7.77M.
Cadian Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 5 quarters.
Cadian Capital Management's BioMarin Pharmaceuticals position peaked at $43.8M in Q2 2015.
391 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2016.

Based on Cadian Capital Management's 13F filing for Q1 2016, filed 13 May 2016.